Previous close | 84.06 |
Open | 84.15 |
Bid | 82.12 x N/A |
Ask | 86.33 x N/A |
Day's range | 83.65 - 84.74 |
52-week range | 73.79 - 94.77 |
Volume | |
Avg. volume | 967,778 |
Market cap | 193.116B |
Beta (5Y monthly) | 0.49 |
PE ratio (TTM) | 26.24 |
EPS (TTM) | 3.21 |
Earnings date | N/A |
Forward dividend & yield | 3.20 (3.78%) |
Ex-dividend date | 09 Mar 2023 |
1y target est | N/A |
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS)1,2 iDFS benefit remains consistent across key patient subgroups; among patients with stage II and stage III tumors, Kisqali lowered risk by 30% and 24.5%, respectively1,2 Latest analysis continues to show a well-tolerated safety profile in line with pre
AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
Novartis (NVS) obtains FDA approval for Fabhalta, the first oral monotherapy for treating adults with PNH.